Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Calidi Biotherapeutics, Inc. (CLDI)
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series B and C warrants to purchase up to an aggregate of 10,698,000 shares of the Company’s common stock at a reduced exercise price of $0.20. The Series B and C warrants, issued in April 2024, have a term of twelve months and four months, respectively. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.1 million, prior to deducting placement agent fees and estimated offering expenses.Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase up to 10,698,000 shares
Show less
Read more
Impact Snapshot
Event Time:
CLDI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDI alerts
High impacting Calidi Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDI
News
- Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of DirectorsBusiness Wire
- Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13Business Wire
- Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsBusiness Wire
- Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
CLDI
Sec Filings
- 6/26/24 - Form 8-K
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- CLDI's page on the SEC website